Effect of PYLOSHOT® in eradicating Helicobacter pylori

The effect of using probiotic PYLOSHOT® as an adjuvant treatment for Helicobacter pylori eradication: a double-blind randomized controlled clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090614002032N6

Enrollment

960

Registered

2023-04-11

Start date

2023-04-29

Completion date

Unknown

Last updated

2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection. Helicobacter pylori [H. pylori] as the cause of diseases classified elsewhere

Interventions

Intervention 1: Intervention group 1: Helicobacter pylori eradication regimen based on furazolidone along with PYLOSHOT® capsules containing 100 mg of Lactobacillus Reuteri, 2 capsules daily in the mo

Eligibility

Sex/Gender

All

Age

35 Years to 70 Years

Inclusion criteria

Inclusion criteria: Positive H. pylori stool antigen test Willing to participate in the study

Exclusion criteria

Exclusion criteria: Negative H. pylori stool antigen test Suffering from any incurable disease Pregnancy and breastfeeding

Design outcomes

Primary

Measure	Time frame
Number of people with negative Helicobacter pylori antigen test in stool. Timepoint: 8 weeks after intervention. Method of measurement: HELICOBACTER PYLORI Ag TEST.	—

Secondary

Measure	Time frame
Clinical symptoms (Digestive disorders and problems). Timepoint: Before intervention and after intervention. Method of measurement: follow-up questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarhad Pourfarzi

Ardabil University of Medical Sciences

farhad.pourfarzi@gmail.com+98 45 3326 2925

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026